Advaxis, Inc. (NASDAQ:ADXS) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday.

A number of other equities analysts have also weighed in on the company. Cantor Fitzgerald set a $19.00 target price on Advaxis and gave the stock a “buy” rating in a research note on Thursday, July 6th. BidaskClub upgraded Advaxis from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. Finally, HC Wainwright set a $23.00 target price on Advaxis and gave the stock a “buy” rating in a research note on Wednesday, June 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $22.00.

Advaxis (ADXS) traded up 2.92% during mid-day trading on Friday, reaching $7.41. The company had a trading volume of 472,768 shares. The stock’s market capitalization is $299.82 million. The stock has a 50 day moving average price of $6.50 and a 200-day moving average price of $7.54. Advaxis has a 12-month low of $5.70 and a 12-month high of $12.66.

COPYRIGHT VIOLATION NOTICE: “Advaxis, Inc. (ADXS) Upgraded to “Sell” by ValuEngine” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/09/advaxis-inc-adxs-upgraded-to-sell-by-valuengine.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN increased its stake in Advaxis by 0.8% in the 1st quarter. Wells Fargo & Company MN now owns 43,669 shares of the biotechnology company’s stock worth $356,000 after acquiring an additional 360 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in Advaxis by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 129,321 shares of the biotechnology company’s stock worth $840,000 after acquiring an additional 817 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Advaxis by 4.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 22,000 shares of the biotechnology company’s stock worth $180,000 after acquiring an additional 1,000 shares during the last quarter. SG Americas Securities LLC increased its stake in Advaxis by 2.9% in the 1st quarter. SG Americas Securities LLC now owns 49,333 shares of the biotechnology company’s stock worth $403,000 after acquiring an additional 1,398 shares during the last quarter. Finally, American International Group Inc. increased its stake in Advaxis by 7.6% in the 1st quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 1,459 shares during the last quarter. Institutional investors and hedge funds own 48.78% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.